Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A

被引：7
|
作者：
Freedman, Rachel A. [1 ,7 ]
Graff, Stephanie L. [2 ]
Somerfield, Mark R. [3 ]
Telli, Melinda L. [4 ]
Wolff, Antonio C. [5 ]
Giordano, Sharon H. [6 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Lifespan Canc Inst, Providence, RI USA
[3] Amer Soc Clin Oncol, Alexandria, VA USA
[4] Stanford Univ, Sch Med, Stanford, CA USA
[5] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[6] MD Anderson Canc Ctr, Houston, TX USA
[7] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
来源：
JCO ONCOLOGY PRACTICE | 2022年 / 18卷 / 07期
关键词：
D O I：
10.1200/OP.22.00140
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Still have questions about how to approach incorporating abemaciclib into the adjuvant treatment of breast cancer? Check out ASCO Guidelines Rapid Recommendation for Rapid Answers! @DrRFreedman @DrSGraff @melindatelli @awolff @shgiordano.
引用
收藏
页码：516 / +
页数：5
相关论文
共 50 条
  • [1] Abemaciclib With Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Optimal Adjuvant Chemotherapy and Targeted Therapy Guideline Rapid Recommendation Update
    Giordano, Sharon H.
    Freedman, Rachel A.
    Somerfield, Mark R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (03) : 307 - +
  • [2] Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Mazakazu
    Martin, Miguel
    Shao, Zhimin
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Cortes, Javier
    Neven, Patrick
    Boyle, Frances
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 112 - 113
  • [3] Abemaciclib as adjuvant treatment for high-risk early breast cancer
    Andrades, Ana Ganfornina
    Caballero, Silvia Fenix
    Olid, Alba Salguero
    Emilio, Jesus Alegre Del-Rey
    [J]. FARMACIA HOSPITALARIA, 2024, 48 (02) : 75 - 78
  • [4] monarchE: Abemaciclib plus endocrine Therapy in High-risk Breast Cancer
    Lorenz, Judith
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (03) : 254 - 254
  • [5] Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A
    Vikas, Praveen
    Korde, Larissa A.
    Somerfield, Mark R.
    Hershman, Dawn L.
    [J]. JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 649 - +
  • [6] Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A
    Raab, Rachel
    Ismaila, Nofisat
    Andre, Fabrice
    Stearns, Vered
    Kalinsky, Kevin
    [J]. JCO ONCOLOGY PRACTICE, 2022, 18 (09) : 646 - +
  • [7] Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
    Andre, Fabrice
    Ismaila, Nofisat
    Allison, Kimberly H.
    Barlow, William E.
    Collyar, Deborah E.
    Damodaran, Senthil
    Henry, N. Lynn
    Jhaveri, Komal
    Kalinsky, Kevin
    Kuderer, Nicole M.
    Litvak, Anya
    Mayer, Erica L.
    Pusztai, Lajos
    Raab, Rachel
    Wolff, Antonio C.
    Stearns, Vered
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : 1816 - +
  • [8] Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update
    Korde, Larissa A.
    Somerfield, Mark R.
    Hershman, Dawn L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (15) : 1696 - +
  • [9] FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
    Royce, Melanie
    Osgood, Christy
    Mulkey, Flora
    Bloomquist, Erik
    Pierce, William F.
    Roy, Arpita
    Kalavar, Shyam
    Ghosh, Soma
    Philip, Reena
    Rizvi, Fatima
    Mixter, Bronwyn D.
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (11) : 1155 - +
  • [10] Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update
    Tung, Nadine M.
    Zakalik, Dana
    Somerfield, Mark R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2959 - +
12345